Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny

Indian Immunologicals Limited has firmly rejected warnings issued by Australian authorities alleging counterfeit rabies vaccine circulation linked to Indian manufacturing. The company states that current production batches fully meet international quality and safety standards, and that the alert references outdated or unauthorized distribution channels.

Rabies vaccines are among the most critical biological products globally. India supplies a significant share of the world’s rabies immunization needs, especially across Asia and Africa. Any doubt regarding vaccine authenticity can trigger massive public health disruption.

IIL maintains that the cited irregularities relate to a limited distribution anomaly and not to authorized factory output. The company has emphasized strict GMP compliance, serialization protocols, and batch traceability across its official supply chains.

The controversy highlights the growing fragility of pharmaceutical trust in globalized medicine. As vaccine supply chains become more fragmented, the risk of grey-market diversion and parallel trading rises — even when manufacturers maintain full compliance.

Health agencies worldwide are tightening surveillance, introducing serialization mandates, and expanding cross-border inspection regimes. Vaccine integrity is now considered a matter of national security, not just healthcare.

IIL’s response underscores the need for centralized procurement, verified digital traceability, and controlled cold-chain logistics — especially in life-saving immunization programs.

The incident may accelerate international adoption of blockchain-based batch verifi